The global clinical oncology next generation sequencing market size was valued at USD 628.45 million in 2025 and is projected to grow from USD 695.95 million in 2026 to USD 1574.02 million by 2034, registering a CAGR of 10.74% during the forecast period from 2026 to 2034. North America dominated the clinical oncology next-generation sequencing market with a market share of 42.35% in 2025.
Clinical oncology next-generation sequencing (NGS) refers to the use of advanced sequencing technologies to analyze tumor DNA and RNA for identifying genetic mutations, biomarkers, and other molecular alterations. It supports cancer diagnosis, tumor profiling, treatment selection, companion diagnostics, and disease monitoring, enabling more personalized and precision-based oncology care.
Download a Free Sample To learn more about this report,
Increasing Adoption of Comprehensive Genomic Profiling in Cancer Care
Next-generation sequencing is increasingly being used to evaluate multiple cancer-related genes simultaneously, enabling clinicians to identify mutations, gene fusions, and other genomic alterations that can guide targeted treatment decisions. The expansion of precision oncology and biomarker-driven therapies is strengthening the role of comprehensive genomic profiling in clinical workflows.
Growing Use of Liquid Biopsy and Circulating Tumor DNA Sequencing
Clinical oncology NGS is increasingly expanding beyond tissue biopsies toward blood-based testing using circulating tumor DNA. Liquid biopsy can provide a less invasive approach for identifying genomic alterations and monitoring cancer patients, supporting broader use of NGS when obtaining or repeatedly sampling tumor tissue is difficult.
Growing Adoption of Biomarker-Guided and Targeted Cancer Therapies
The increasing availability of therapies linked to specific genomic alterations is driving demand for NGS-based testing that can identify patients most likely to benefit from targeted treatments. Comprehensive sequencing can evaluate multiple biomarkers from a single clinical specimen, supporting treatment selection as precision oncology becomes more integrated into cancer care.
High Testing Complexity and Interpretation Requirements Limit Wider Clinical Adoption
Clinical oncology NGS requires specialized sequencing instruments, laboratory infrastructure, bioinformatics capabilities, validated workflows, and skilled personnel. The volume and complexity of genomic information generated can also make interpretation difficult, particularly when results include variants whose clinical significance is uncertain.
Expansion of Precision Oncology Trials Creates New Demand for NGS Testing
The continued development of molecularly driven clinical trials is creating opportunities for NGS providers to support patient screening, treatment assignment, and biomarker evaluation. As trials increasingly select participants according to specific genomic alterations, sequencing can become an integral part of identifying eligible patients and evaluating treatment response.
Regulatory and Clinical Validation Requirements Increase Development Complexity
NGS oncology tests must demonstrate analytical validity, clinical relevance, and reliable performance before they can be broadly incorporated into regulated clinical decision-making. Developers also need to maintain performance as sequencing technologies, biomarkers, and associated targeted therapies continue to evolve.
Companion Diagnostics Segment Dominated the Market with 44.87% Share in 2025
The companion diagnostics segment dominated the clinical oncology next-generation sequencing market with a 44.87% share in 2025, reaching USD 281.99 million, and is projected to grow at a CAGR of 16.12% during 2026–2034. Screening accounted for a 38.46% share, reaching USD 241.70 million, while other applications represented 16.67%, reaching USD 104.76 million.
The growing use of genomic biomarkers to guide targeted cancer therapies is supporting demand for companion diagnostics. NGS enables the identification of multiple molecular alterations from tumor samples, helping healthcare providers select appropriate treatments and improve precision oncology outcomes.
Request Customizationto receive a tailored report.
NGS Data Analysis Segment is Projected to Grow at a CAGR of 16.84%
The NGS sequencing segment accounted for a 45.39% share of the clinical oncology next-generation sequencing market in 2025, reaching USD 285.25 million, and is projected to grow at a CAGR of 14.95% during 2026–2034. NGS pre sequencing represented 31.28%, reaching USD 196.58 million, while NGS data analysis accounted for 23.33%, reaching USD 146.62 million, and is projected to grow at the fastest CAGR of 16.84%.
The increasing volume and complexity of genomic data generated during oncology testing is driving demand for advanced data analysis solutions. Bioinformatics platforms and computational tools are increasingly being used to interpret sequencing results, identify clinically relevant mutations, and support treatment decisions.
Targeted Sequencing and Re-Sequencing Segment Dominated the Market with 46.64% Share in 2025
The targeted sequencing and re-sequencing segment dominated the clinical oncology next-generation sequencing market with a 46.64% share in 2025, reaching USD 293.11 million, and is projected to grow at a CAGR of 15.26% during 2026–2034. Whole exome sequencing accounted for a 28.74% share, reaching USD 180.62 million, while whole genome sequencing represented 24.62%, reaching USD 154.72 million.
Targeted sequencing remains widely used in clinical oncology because it enables efficient analysis of specific cancer-related genes and mutations while requiring less sequencing data than broader genomic approaches. Increasing adoption of targeted cancer therapies and biomarker testing is supporting segment growth.
Diagnostic Laboratories Segment is Projected to Grow at a CAGR of 15.74%
The diagnostic laboratories segment accounted for a 47.26% share of the clinical oncology next-generation sequencing market in 2025, reaching USD 297.01 million, and is projected to grow at a CAGR of 15.74% during 2026–2034. Hospitals accounted for a 39.18% share, reaching USD 246.23 million, while other end-users represented 13.56%, reaching USD 85.22 million.
Diagnostic laboratories are increasingly adopting NGS platforms to support molecular tumor profiling, biomarker identification, and precision cancer testing. Growing demand for comprehensive genomic testing and the expansion of specialized oncology diagnostics are supporting the increasing use of NGS in laboratory settings.
Speak to an Analystto discuss market opportunities.
North America dominated the clinical oncology next-generation sequencing market with a 42.35% share in 2025, reaching USD 266.15 million, and is projected to grow at a CAGR of 13.84% during 2026–2034. The region's leading position is supported by advanced molecular diagnostics infrastructure, high adoption of precision oncology, strong cancer research activity, and established reimbursement pathways for genomic testing. The presence of major sequencing and biotechnology companies and widespread use of companion diagnostics are also supporting regional growth.
The US market is supported by advanced healthcare infrastructure, substantial investment in cancer genomics, widespread adoption of tumor profiling, and strong integration of NGS into precision oncology. Supportive regulatory frameworks, reimbursement for genomic testing, and the presence of leading sequencing companies are further contributing to market expansion.
Canada's market is supported by expanding access to molecular diagnostics, public healthcare investment, and growing adoption of genomic testing in cancer care. Increasing integration of precision medicine and expanding oncology testing infrastructure are creating further opportunities for clinical NGS adoption.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe accounted for 27.18% of the clinical oncology next-generation sequencing market in 2025, reaching USD 170.81 million, and is projected to grow at a CAGR of 14.21% during 2026–2034. Growth is supported by increasing adoption of personalized medicine, national cancer genomics initiatives, advanced healthcare infrastructure, and expanding access to molecular diagnostics. Collaboration between research institutions, healthcare providers, and biotechnology companies is also supporting the development of NGS-based oncology applications.
The UK market is supported by government-backed genomics initiatives, strong precision oncology research, and established healthcare and diagnostic infrastructure. Increasing use of genomic testing for cancer classification, treatment selection, and biomarker identification is supporting the integration of NGS into clinical oncology.
Germany's market benefits from well-established healthcare infrastructure, strong investment in cancer genomics research, and increasing adoption of precision medicine. Growing use of advanced molecular diagnostics and NGS testing for tumor profiling and therapy selection is supporting market development.
Asia Pacific accounted for 21.64% of the clinical oncology next-generation sequencing market in 2025, reaching USD 136.00 million, and is projected to grow at the fastest CAGR of 17.38% during 2026–2034. Growth is supported by rising cancer prevalence, expanding healthcare infrastructure, increasing adoption of precision medicine, and growing investment in genomic research. Government-supported genomics initiatives and expanding clinical laboratory networks are further accelerating NGS adoption across the region.
China's market is supported by increasing cancer incidence, expanding molecular diagnostics infrastructure, and growing government and industry investment in genomic medicine. Increasing adoption of precision oncology, targeted therapies, and clinical sequencing is supporting the expansion of NGS-based cancer testing.
Japan's market benefits from advanced healthcare infrastructure, established oncology centers, and increasing adoption of genomic medicine. Growing use of NGS for tumor profiling and companion diagnostic testing, supported by healthcare coverage frameworks for targeted oncology therapies, is contributing to market growth.
Middle East and Africa accounted for 3.71% of the clinical oncology next-generation sequencing market in 2025, reaching USD 23.32 million, and is projected to grow at a CAGR of 11.82% during 2026–2034. Growth is supported by improving healthcare infrastructure, increasing awareness of precision medicine, rising cancer burden, and gradual expansion of advanced molecular diagnostic services. Growing investment in genomic testing and specialized oncology centers is also creating opportunities for NGS adoption.
The UAE market is supported by investments in advanced healthcare infrastructure, increasing adoption of precision medicine, and growing demand for specialized oncology diagnostics. The expansion of modern hospitals, diagnostic laboratories, and genomic testing capabilities is supporting the adoption of NGS technologies.
South Africa's market is supported by expanding diagnostic laboratory capabilities, increasing cancer research activity, and growing awareness of molecular testing. Improvements in healthcare infrastructure and increasing demand for advanced cancer diagnostics are contributing to the gradual adoption of clinical oncology NGS.
The clinical oncology next-generation sequencing market is competitive, with leading companies focusing on sequencing platforms, oncology panels, companion diagnostics, bioinformatics, molecular profiling, and integrated genomic testing solutions. Key players include Illumina, Inc., Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Hoffmann-La Roche Ltd, QIAGEN N.V., Foundation Medicine, Inc., Bio-Rad Laboratories, Inc., PerkinElmer, Inc., Becton, Dickinson and Company, and PacBio. Companies are increasingly expanding targeted sequencing, comprehensive genomic profiling, liquid biopsy, and data-analysis capabilities to support precision oncology and biomarker-driven treatment decisions. Illumina, for example, offers oncology-focused NGS panels and integrated sequencing and bioinformatics solutions for cancer research and clinical applications.
Foundation Medicine, Inc.
Foundation Medicine is strengthening its position through comprehensive genomic profiling and NGS-based companion diagnostic solutions for precision oncology. Its FoundationOne CDx and FoundationOne Liquid CDx platforms support the identification of genomic alterations and biomarkers that can help guide targeted therapy decisions across multiple cancer types.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
3D Cell Culture Market Size, Share, Growth, Analysis, Report, 2034
3D Bioprinting Market Size, Share, Growth, Analysis, Report, 2034
United Kingdom Epigenetics Market Size, Trends, Top Share and Forecast to 2034
Bovine Serum Market Size, Share, Growth, Analysis, Report, 2034
Asia Pacific TB Diagnostics Market Size, Share & Growth Graph by 2034
South Korea Epigenetics Market Size, Supply & Growth Report 2034
We are featured on:
sales@straitsresearch.com